NClip

Psychotropic Medications

10 min read

Psychotropic Medications

Key Points

  • Psychotropic medications act on neurotransmitters (serotonin, dopamine, GABA, norepinephrine) to treat mental health disorders
  • Antidepressants (SSRIs/SNRIs): First-line for depression and most anxiety disorders; onset is delayed (often 4-8 weeks for noticeable mood response); watch for serotonin syndrome and early-treatment suicidality
  • Antipsychotics: First-gen → EPS/tardive dyskinesia; Second-gen (atypical) → metabolic syndrome; clozapine requires REMS monitoring for agranulocytosis
  • Lithium: Narrow therapeutic index (0.6–1.2 mEq/L); monitor levels every 10–12 hours after last dose; NSAIDs and diuretics increase lithium toxicity risk
  • Benzodiazepines: Schedule IV; GABA-A agonists; flumazenil reversal; NEVER abrupt discontinuation
  • ADHD stimulants: Schedule II with misuse/diversion risk; monitor BP/HR and pediatric growth, and escalate chest pain, syncope, mania/psychosis, or priapism
  • All psychotropic medications require monitoring for suicidal ideation — especially during initiation or dose changes

Neurotransmitter Basis

Psychotropic medications target imbalances in brain neurotransmitters:

NeurotransmitterRoleDeficiency/ExcessDrug Classes Targeting It
Serotonin (5-HT)Mood, sleep, appetiteDeficiency → depression, anxietySSRIs, SNRIs, antipsychotics
Norepinephrine (NE)Alertness, arousalExcess → anxiety; deficiency → depressionSNRIs, TCAs, MAOIs
DopamineReward, movementExcess → psychosis; deficiency → EPSAntipsychotics (block), antidepressants
GABAInhibitory (calming)Deficiency → anxiety, seizuresBenzodiazepines, buspirone
GlutamateExcitatoryExcess → mania, neurotoxicityLithium (reduces)

Class 1: Antidepressants

First-line pharmacotherapy for major depressive disorder, anxiety disorders, OCD, PTSD, and panic disorder.

Onset: Initial benefit may begin after 2+ weeks, but noticeable mood response often requires 4-8 weeks — patients must continue even if they feel no early benefit.

Major Subclasses:

  • SSRIs: Sertraline, fluoxetine, escitalopram — preferred first-line; block serotonin reuptake
  • SNRIs: Venlafaxine, duloxetine — block serotonin + norepinephrine reuptake
  • Trazodone (SARI): Commonly used off-label as sedative for insomnia
  • TCAs: Amitriptyline, nortriptyline — high anticholinergic burden; lethal overdose risk
  • MAOIs: Phenelzine, tranylcypromine — severe dietary and drug interactions (tyramine → hypertensive crisis)

Black Box Warning — Antidepressants and Suicidality

All antidepressants carry an FDA Black Box Warning for increased risk of suicidal thinking and behavior in children, adolescents, and young adults under age 25. Monitor closely during the first weeks of treatment or dose changes.

For treatment-resistant depression after at least two antidepressant trials, supervised intranasal esketamine may be used with ongoing oral antidepressant therapy.

See antidepressants for complete drug profiles, adverse effects, and nursing management.

Class 2: Antipsychotics

Used to treat schizophrenia, schizoaffective disorder, bipolar mania, and psychotic features of other disorders.

First-Generation (Typical) Antipsychotics

Mechanism: Block D2 (dopamine) receptors in the limbic system and basal ganglia.

Agents: Chlorpromazine (Thorazine), haloperidol (Haldol), perphenazine, fluphenazine.

Primary Adverse Effects:

  • Extrapyramidal Symptoms (EPS): Akathisia (restlessness), dystonia (acute muscle contractions), parkinsonism (tremor, rigidity, bradykinesia)
  • Tardive Dyskinesia (TD): Involuntary repetitive movements persisting ≥1 month (tongue thrusting, grimacing, lip smacking) — may be irreversible
  • Anticholinergic effects (dry mouth, constipation, urinary retention), sedation
  • Acute dystonia involving laryngeal muscles is an airway emergency; treat rapidly with parenteral diphenhydramine or benztropine.

Second-Generation (Atypical) Antipsychotics

Mechanism: Block D2 + serotonin (5-HT2A) receptors → treat positive symptoms (hallucinations, delusions) AND negative symptoms (flat affect, social withdrawal) with less EPS risk.

Agents: Risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, paliperidone, lurasidone.

Lumateperone is also used in bipolar-depression pathways as monotherapy or adjunctive therapy with lithium/valproate.

Primary Adverse Effects:

  • Metabolic Syndrome: Weight gain, hyperglycemia, hypertension, elevated triglycerides — monitor weight, blood glucose, lipids
  • QTc prolongation risk (ziprasidone > others) — baseline ECG recommended
  • Orthostatic hypotension, sedation
  • Long-acting injectable formulations may improve adherence (frequency varies by agent: twice monthly, monthly, every 3 months, or every 6 months).

Clozapine — Treatment-Resistant Schizophrenia

Indication: Reserved for schizophrenia unresponsive to ≥2 adequate antipsychotic trials.

Unique Risk: Agranulocytosis (potentially fatal) — requires REMS monitoring program with regular absolute neutrophil count (ANC) monitoring. Also associated with myocarditis risk.

Neuroleptic Malignant Syndrome (NMS)

Rare but life-threatening complication of antipsychotics: fever, severe muscle rigidity (“lead pipe”), altered consciousness, and autonomic instability. Immediately discontinue antipsychotic and provide supportive care.

Symptom response timing varies: agitation/hallucinations may improve in days, delusions usually improve over weeks, and full therapeutic effect can take up to about 6 weeks.

Class 3: Mood Stabilizers

Used primarily for bipolar disorder (acute mania, maintenance, bipolar depression).

Lithium (Gold Standard)

Mechanism: Affects synthesis, release, and reuptake of multiple neurotransmitters — reduces excitatory neurotransmission (dopamine, glutamate) and increases inhibitory GABA transmission.

Primary Role: First-line mood stabilizer for acute mania and maintenance in bipolar disorders; can begin reducing manic symptoms within about 1-3 weeks and has antisuicidal benefit.

Narrow Therapeutic Index: Requires routine serum level monitoring.

  • Blood levels drawn 10–12 hours after last dose
  • Therapeutic range: 0.6–1.2 mEq/L (maintenance closer to 0.6)
  • Some acute-treatment protocols target upper therapeutic bands (for example 0.8-1.2 mEq/L); always follow current prescriber target range and trend.
  • Toxicity levels and signs:
Serum LevelClinical Signs
1.5–2.5 mEq/LLethargy, tremors, nausea, vomiting
2.5–3.5 mEq/LConfusion, agitation, delirium (delirium), tachycardia
>3.5 mEq/LComa, seizures, hyperthermia, hypotension

Critical Drug Interactions: NSAIDs and diuretics increase lithium levels → toxicity; theophylline decreases lithium levels. Other interaction pathways include serotonergic medications (serotonin-toxicity risk), carbamazepine (CNS-toxicity burden), and neuromuscular-blocking agents (prolonged effect risk).

Nursing Key Points:

  • Administer with food; maintain adequate hydration (1.5–3 L/day)
  • If GI distress occurs, divided dosing may improve tolerance.
  • Keep dietary sodium intake consistent; abrupt sodium reduction raises toxicity risk, while abrupt sodium increase can lower lithium toward subtherapeutic levels.
  • Avoid or use only specialist-guided therapy in significant renal/cardiovascular disease, severe dehydration, or sodium depletion states; concurrent diuretic therapy materially raises toxicity risk.
  • Monitor kidney function and thyroid function (lithium causes hypothyroidism with long-term use)
  • Avoid use in Addison-disease physiology because sodium-loss states can accelerate lithium reabsorption and toxicity.
  • Monitor calcium/parathyroid trends with long-term therapy because lithium can contribute to hyperparathyroid patterns.
  • Monitor for nephrogenic diabetes-insipidus pattern (polyuria/polydipsia) due to ADH blockade.
  • Obtain and trend baseline safety data as ordered (for example ECG, CBC, electrolytes, liver function, and TSH) during ongoing lithium therapy.
  • Teach early toxicity cues: diarrhea, vomiting, drowsiness, muscular weakness, and poor coordination.
  • Escalate urgently for fainting, palpitations/abnormal heartbeat, severe light-headedness, or dyspnea because lithium can be associated with ECG abnormalities and serious dysrhythmia risk.
  • In suspected toxicity, notify provider, hold lithium, and support hydration; severe cases may require dialysis.
  • Treat lithium level above about 2.5 mEq/L as a medical emergency even when symptoms are not yet obvious.
  • Generally avoid in pregnancy and breastfeeding unless benefit-risk review supports continuation.
  • Pediatric safety remains limited; many references avoid routine use in children under 12 years unless specialist-directed.

Anticonvulsant Mood Stabilizers

Used as adjuncts or alternatives to lithium in bipolar disorder:

  • Valproic acid/divalproex sodium (Depakote): Acute mania (including selected rapid-cycling patterns); therapeutic range about 50-125 mcg/mL; monitor liver function, platelets, and pancreatitis cues (amylase/lipase).
  • Carbamazepine (Tegretol): Therapeutic range about 4-12 mcg/mL; monitor CBC and liver function for marrow/liver toxicity risk; hold and escalate when significant toxicity is suspected (for example level above about 20 mcg/mL with neurologic/GI symptoms).
  • Lamotrigine (Lamictal): Bipolar depression maintenance; must titrate slowly to prevent Stevens-Johnson syndrome (severe rash).
  • Topiramate/Oxcarbazepine contexts: Used in selected treatment-resistant mania pathways; monitor for class-relevant adverse effects such as visual/cognitive effects (topiramate) and hyponatremia (oxcarbazepine).

See anticonvulsants for complete anticonvulsant drug profiles.

Class 4: Anxiolytics

Used for anxiety disorders, acute agitation, and panic.

  • Benzodiazepines (lorazepam, alprazolam, diazepam): Schedule IV; GABA-A agonists; fast onset; reversal agent = flumazenil; NEVER stop abruptly; + opioids → Boxed Warning for respiratory depression
  • Buspirone: Non-addictive alternative; serotonin 5-HT1A partial agonist; onset 2–4 weeks; no sedation
  • SSRIs/SNRIs: First-line for chronic anxiety disorders

See anxiolytics for complete profiles.

Class 5: Sedative-Hypnotics

Used for insomnia when nonpharmacologic measures have failed.

  • Z-drugs (zolpidem, eszopiclone, zaleplon): Schedule IV; GABA-A agonists; Beers Criteria — avoid in older adults
  • Ramelteon: Melatonin MT1/MT2 agonist; NOT controlled; preferred in older adults
  • Orexin antagonists (suvorexant): Schedule IV; suppress wakefulness drive

See sedative-hypnotics for complete profiles.

Class 6: Stimulants and Nonstimulants (ADHD/Narcolepsy)

Used for ADHD in children, adolescents, and adults when indicated as part of a broader treatment plan.

Mechanism: Block norepinephrine and dopamine reuptake, increasing synaptic catecholamines; in ADHD this can improve focus and self-control despite a paradoxical calming effect.

Stimulant Agents: Methylphenidate, amphetamine, dextroamphetamine, lisdexamfetamine, dexmethylphenidate.

Safety Profile:

  • Schedule II controlled substances with high abuse/dependence and diversion potential.
  • Common adverse effects: insomnia, appetite suppression/weight loss, abdominal pain, headache.
  • Less common adverse effects: motor/vocal tics, personality flattening.
  • Serious adverse effects requiring urgent escalation: chest pain/syncope, severe hypertension symptoms, mania/psychosis, peripheral vascular symptoms, priapism.
  • Contraindicated with MAOIs and within 14 days after MAOI discontinuation.
  • Avoid in clients with serious structural cardiac disease (for example structural abnormalities, cardiomyopathy, significant dysrhythmia, or coronary artery disease) unless specialist-directed risk/benefit justifies use.
  • Review for additional contraindication patterns (for example glaucoma, hyperthyroidism, and severe uncontrolled psychiatric symptoms) before initiation.

Nursing Key Points:

  • Assess misuse/diversion risk before and during treatment; teach locked storage, no sharing, and take-back disposal.
  • Monitor blood pressure and pulse regularly.
  • In pediatric clients, monitor appetite, weight, and linear growth.
  • Avoid alcohol with extended-release stimulant formulations.
  • Give extended-release methylphenidate in the morning and do not crush/chew/divide modified-release capsules.
  • Teach families to monitor and report digital ischemia/Raynaud-type signs (numb/cool/painful fingers or toes, color change pale-blue-red).
  • Teach clients with hypertension history to avoid OTC sympathomimetic products (for example pseudoephedrine/phenylephrine) unless prescriber-approved.
  • Dose/frequency optimization commonly requires weekly follow-up during the first 1-3 months.

Nonstimulant Pathways:

  • Atomoxetine/viloxazine (NRI pathways): Useful when stimulant intolerance or diversion risk is high; monitor for emergent suicidal thoughts during initiation and dose changes.
  • Alpha-2 agonists (guanfacine/clonidine): Can reduce hyperactivity/impulsivity but may cause sedation, bradycardia, and hypotension; avoid abrupt clonidine discontinuation due to rebound-hypertension risk.
  • Wake-promoting narcolepsy pathways: Modafinil, pitolisant, and solriamfetol are used for excessive daytime sleepiness; modafinil can reduce effectiveness of oral hormonal contraception.
  • Sodium oxybate: Treats narcolepsy-related cataplexy/excessive daytime sleepiness but has substantial misuse and respiratory-depression risk and is dispensed through a restricted REMS program.

See attention-deficit-hyperactivity-disorder for ADHD-focused nursing assessment and care planning.

Nursing Assessment

Before Initiating Any Psychotropic Medication:

  • Complete mental status exam including suicidal ideation
  • Medication history: prior psychiatric medications and response
  • Substance use history (interactions with CNS depressants)
  • Physical exam: baseline weight, vital signs, metabolic panel (especially for antipsychotics)
  • Pregnancy/breastfeeding status

Ongoing Monitoring:

  • Suicidal ideation — especially first 1–4 weeks
  • Medication adherence (psychotropic medications often discontinued prematurely)
  • Adverse effects specific to each drug class (EPS, metabolic syndrome, lithium toxicity signs)
  • Stimulant safety surveillance when prescribed (BP/HR, appetite/weight, growth, sleep, and misuse/diversion signals)
  • Therapeutic drug levels where required (lithium, some anticonvulsants)

Patient Education:

  • Do not stop medications abruptly without provider guidance
  • Therapeutic effect takes time — set realistic expectations (2–4 weeks for antidepressants, 1–3 weeks for lithium)
  • Report lithium toxicity cues immediately: persistent diarrhea/vomiting, drowsiness, muscle weakness, ataxia/lack of coordination, tinnitus, or large-volume dilute urine.
  • Avoid driving or operating heavy machinery when first starting lithium until alertness effects are known.
  • Report new or worsening suicidal thoughts, unusual behaviors, or severe adverse effects immediately
  • Avoid alcohol and CNS depressants (especially with benzodiazepines)
  • Use trusted medication-information resources: clinician-facing FDA label data (for example DailyMed) and patient-facing plain-language resources (for example MedlinePlus and NAMI education pages)

Self-Check

  1. A patient on lithium reports nausea, hand tremors, and excessive thirst. What do you suspect, and what serum level would indicate toxicity requiring immediate intervention?
  2. A patient started on an antipsychotic 2 months ago develops involuntary lip smacking and tongue thrusting. What extrapyramidal complication do you suspect, and what is the significance of its persistence?
  3. A provider orders clozapine for a patient with treatment-resistant schizophrenia. What mandatory monitoring program must be in place before dispensing?

Graph View